Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 20, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the local directory fallback.
Local D1 index available.
Filters: Condition: Sinusitis Clear all
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
33
States / cities
Birmingham, Alabama • Arcadia, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 19, 2026, 6:46 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis, Cystic Fibrosis in Children, Olfactory Disorder, Olfactory Impairment
Interventions
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Years to 8 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Aurora, Colorado • Iowa City, Iowa • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 20, 2026, 12:21 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Mometasone furoate nasal spray (MFNS), lunsekimig
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
La Jolla, California • Roseville, California • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 19, 2026, 6:46 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 19, 2026, 6:46 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • La Mesa, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 19, 2026, 6:46 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 99 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 18, 2026, 10:28 AM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Ivacaftor, standard of care treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Apr 23, 2026, 7:09 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Tezepelumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Chicago, Illinois • Chestnut Hill, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 19, 2026, 6:46 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
OPN-375, Placebo
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Gilbert, Arizona • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced May 17, 2026, 2:38 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Rhinosinusitis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced May 17, 2026, 2:38 PM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Acute Sinusitis, Sinus Infection
Interventions
Budesonide nasal spray, Placebo, amoxicillin/clavulanate potassium
Drug
Lead sponsor
Daniel Merenstein
Other
Eligibility
18 Years to 75 Years
Enrollment
3,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Apr 29, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Chronic Rhinosinusitis (CRS), Inferior Turbinate Hypertrophy, Rhinitis, Vasomotor, Thyroid Nodules, Vocal Fold Immobility
Interventions
Lavender Aromatherapy, Placebo Aromatherapy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced May 18, 2026, 1:22 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Smell Loss
Interventions
Dupilumab - Standard Dose
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced May 20, 2026, 11:21 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Irrigation head position
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced May 10, 2026, 5:23 PM EDT
Not yet recruiting Not applicable Interventional
View directory record Official record
Conditions
Anxiety, Chronic Rhinosinusitis (CRS), Dysphonia, Eustachian Tube Dysfunction, Nasal Obstruction, Nasal Polyp, Pain, Subglottic Stenosis (SGS)
Interventions
Virtual reality headset or goggles
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 1:31 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Anosmia, COVID-19, Depression, Hyposomia, Influenza, Normosomia, Parosmia, Respiratory Tract Infection, Rhinosinusitis, Smell Disorder
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 11:21 AM EDT
Not yet recruiting Not applicable Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions
Airiver ESSpand DCB, ESS
Combination Product · Procedure
Lead sponsor
Airiver Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Brooklyn Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 18, 2026, 10:28 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 19, 2026, 6:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1, Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced May 20, 2026, 11:20 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
COPD, Covid19, Cystic Fibrosis, PCD - Primary Ciliary Dyskinesia, Sinusitis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced May 19, 2026, 6:47 PM EDT
Enrolling by invitation Phase 3 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 19, 2026, 6:46 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
lunsekimig, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Jolla, California • Roseville, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 19, 2026, 6:46 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Dupilumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Charleston, South Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 18, 2026, 11:59 AM EDT
Enrolling by invitation Not applicable Interventional
View directory record Official record
Conditions
Allergic Rhinitis, Sinusitis
Interventions
QHSLab Digital Tools (AME and ARIS)
Other
Lead sponsor
QHSLab, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced May 19, 2026, 6:25 PM EDT